Suppr超能文献

临床前制剂:见解、策略及实际考量

Preclinical formulations: insight, strategies, and practical considerations.

作者信息

Shah Sanket M, Jain Ankitkumar S, Kaushik Ritu, Nagarsenker Mangal S, Nerurkar Maneesh J

机构信息

Department of Pharmaceutics, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai, 400098, India.

出版信息

AAPS PharmSciTech. 2014 Oct;15(5):1307-23. doi: 10.1208/s12249-014-0156-1. Epub 2014 Jun 12.

Abstract

A lot of resources and efforts have been directed to synthesizing potentially useful new chemical entities (NCEs) by pharmaceutical scientists globally. Detailed physicochemical characterization of NCEs in an industrial setup begins almost simultaneously with preclinical testing. Most NCEs possess poor water solubility posing bioavailability issues during initial preclinical screening, sometimes resulting in dropping out of an NCE with promising therapeutic activity. Selection of right formulation approach for an NCE, based on its physicochemical properties, can aid in improving its solubility-related absorption and bioavailability issues. The review focuses on preclinical formulations stressing upon different preclinical formulation strategies and deciphers the understanding of formulation approaches that could be employed. It also provides detailed information related to a vast pool of excipients available today, which is of immense help in designing preclinical formulations. Few examples mentioned, throw light on key aspects of preclinical formulation development. The review will serve as an important guide for selecting the right strategy to improve bioavailability of NCEs for academic as well as industrial formulation scientists.

摘要

全球制药科学家投入了大量资源和精力来合成潜在有用的新化学实体(NCE)。在工业环境中,NCE的详细物理化学表征几乎与临床前测试同时开始。大多数NCE的水溶性较差,在初始临床前筛选期间会出现生物利用度问题,有时会导致具有潜在治疗活性的NCE被淘汰。根据NCE的物理化学性质选择合适的制剂方法,有助于改善其与溶解度相关的吸收和生物利用度问题。本综述重点关注临床前制剂,强调不同的临床前制剂策略,并解读可采用的制剂方法。它还提供了与当今大量可用辅料相关的详细信息,这对设计临床前制剂有极大帮助。文中提到的一些例子阐明了临床前制剂开发的关键方面。本综述将为学术和工业制剂科学家选择提高NCE生物利用度的正确策略提供重要指导。

相似文献

1
Preclinical formulations: insight, strategies, and practical considerations.临床前制剂:见解、策略及实际考量
AAPS PharmSciTech. 2014 Oct;15(5):1307-23. doi: 10.1208/s12249-014-0156-1. Epub 2014 Jun 12.
6
Developing early formulations: practice and perspective.开发早期配方:实践与展望。
Int J Pharm. 2007 Aug 16;341(1-2):1-19. doi: 10.1016/j.ijpharm.2007.05.049. Epub 2007 May 26.
7
Comprehensive assessment of ADMET risks in drug discovery.药物研发中ADMET风险的综合评估。
Curr Pharm Des. 2009;15(19):2195-219. doi: 10.2174/138161209788682514.
8
Impact of preformulation on drug development.制剂前研究对药物研发的影响。
Expert Opin Drug Deliv. 2013 Sep;10(9):1239-57. doi: 10.1517/17425247.2013.783563. Epub 2013 Mar 27.
9
Development of Cordycepin Formulations for Preclinical and Clinical Studies.蛹虫草素制剂的临床前和临床研究进展。
AAPS PharmSciTech. 2017 Nov;18(8):3219-3226. doi: 10.1208/s12249-017-0795-0. Epub 2017 May 30.

引用本文的文献

5
Hot-Melt Extrusion: a Roadmap for Product Development.热熔挤出:产品开发路线图。
AAPS PharmSciTech. 2021 Jun 17;22(5):184. doi: 10.1208/s12249-021-02017-7.

本文引用的文献

2
In vivo toxicology of excipients commonly employed in drug discovery in rats.大鼠体内药物研发常用辅料的毒理学研究
J Pharmacol Toxicol Methods. 2013 Sep-Oct;68(2):284-295. doi: 10.1016/j.vascn.2013.02.009. Epub 2013 Mar 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验